MEI PHARMA, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.13 USD | +0.64% |
|
-0.96% | -46.04% |
Presenter SpeechStephen Willey (Analysts)All right. Good afternoon, everyone. I'm Stephen Will...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
MEI Pharma, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel and differentiated cancer therapies. Its drug candidate pipeline includes Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib is a potent and selective orally administered CDK9 inhibitor. Voruciclib is being studied in a Phase 1 trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) and B-cell malignancies as a single-agent, and in combination with the B-cell lymphoma 2 (BCL) inhibitor venetoclax (marketed as Venclexta) in patients with AML. ME-344 is a novel mitochondrial inhibitor drug candidate that demonstrates tumor selective activity in pre-clinical studies. It targets the OXPHOS pathway involved in the production of adenosine triphosphate (ATP).
Calendar
2024-08-28
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
3.11
USD
Average target price
22.67
USD
Spread / Average Target
+628.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -46.04% | 20.72M | |
| +42.32% | 54.04B | |
| +43.57% | 41.96B | |
| -1.33% | 41.92B | |
| -7.59% | 28.35B | |
| +11.69% | 26.35B | |
| -22.21% | 19B | |
| +7.65% | 13B | |
| +28.43% | 12.28B | |
| +25.67% | 12.19B |
- Stock Market
- Equities
- MEIP Stock
- News MEI Pharma, Inc.
- Transcript : MEI Pharma, Inc. Presents at 2020 Stifel Virtual Healthcare Conference, Nov-16-2020 04